Device Trial Radar · NCT07675395
Atrial Remodeling After PFA Substrate Modification for Persistent AF (PeAF)
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Taipei Veterans General Hospital, TaiwanGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Boston Scientific Corporation
- First posted
- Jun 30, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Atrial fibrillation (AF) is associated with both electrical and structural remodeling of the left atrium. While successful catheter ablation has been shown to reverse some aspects of atrial remodeling, the impact of pulsed-field ablation (PFA) - a non-thermal ablation technology that selectively targets cardiomyocytes while sparing surrounding structures - on atrial remodeling in patients with persistent AF undergoing extensive substrate modification remains unclear. This is a prospective, single-center, single-arm observational study conducted at Taipei Veterans General Hospital. The study will enroll 30 patients with persistent atrial fibrillation who undergo pulmonary vein isolation (PVI) and extensive substrate modification using the FARAWAVE / FARADRIVE Catheter and FARASTAR System. The primary objective is to evaluate left atrial structural remodeling following PFA, including changes in LA size, atrial strain, extent of atrial fibrosis, and atrial hemodynamic function. The secondary objective is to assess AF-free survival between 3 and 12 months after the procedure, and its relationship to atrial remodeling. All participants will be followed for 12 months, with an interim analysis conducted once all subjects complete their 6-month follow-up.
Conditions
- Persistent Atrial Fibrillation
- Atrial Fibrillation (AF)
- Atrial Remodeling
- Pulsed Field Ablation
Interventions
Pulsed-Field Ablation with FARAWAVE Catheter SystemDevice
Pulsed-field ablation is performed using the FARAWAVE / FARADRIVE Catheter and FARASTAR System (Boston Scientific) under deep sedation or general anesthesia. PFA is delivered to achieve pulmonary vein isolation and posterior wall isolation, with additional substrate modification at the operator's discretion. Invasive hemodynamic assessment is performed pre- and post-PFA during the index procedure and repeated at approximately 3 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Left Atrial Anteroposterior DiameterTime frame: Baseline, 3 months, 6 months, and 12 months post-procedure
- Change in Left Atrial Volume IndexTime frame: Baseline, 3 months, 6 months, and 12 months post-procedure
- Change in Left Atrial Reservoir StrainTime frame: Baseline, 3 months, 6 months, and 12 months post-procedure
8 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taipei Veterans General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.